About Asterias Biotherapeutics (NYSEMKT:AST)
Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NYSEMKT:AST
- CUSIP: N/A
- Web: asteriasbiotherapeutics.com
- Market Cap: $137.44 million
- Outstanding Shares: 49,978,000
- 50 Day Moving Avg: $3.23
- 200 Day Moving Avg: $3.31
- 52 Week Range: $2.60 - $5.80
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.74
- P/E Growth: 0.00
- Annual Revenue: $6.15 million
- Price / Sales: 22.35
- Book Value: $0.74 per share
- Price / Book: 3.72
- EBITDA: ($29,790,000.00)
- Net Margins: -2,762.03%
- Return on Equity: -86.25%
- Return on Assets: -66.19%
- Average Volume: 166,749 shs.
- Beta: 1.58
- Short Ratio: 20.53
Frequently Asked Questions for Asterias Biotherapeutics (NYSEMKT:AST)
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEMKT:AST) announced its quarterly earnings results on Monday, August, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.07. The business earned $1.53 million during the quarter, compared to the consensus estimate of $1.14 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. View Asterias Biotherapeutics' Earnings History.
Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?
2 brokers have issued 12 month price objectives for Asterias Biotherapeutics' stock. Their predictions range from $10.00 to $10.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $10.00 in the next year. View Analyst Ratings for Asterias Biotherapeutics.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include Horizon Discovery Group PLC (HZD), Curis (CRIS), Chromadex Corp (CDXC), Compugen (CGEN), Pluristem Therapeutics (PSTI), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Silence Therapeutics plc (SLN), Merrimack Pharmaceuticals (MACK), Nabriva Therapeutics AG (NBRV), Advaxis (ADXS), Palatin Technologies (PTN), Oramed Pharmaceuticals (ORMP), CASI Pharmaceuticals (CASI), OncoMed Pharmaceuticals (OMED), Zynerba Pharmaceuticals (ZYNE), GTx (GTXI) and Regulus Therapeutics (RGLS).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Don M. Bailey, Chairman of the Board
- Michael H. Mulroy, President, Chief Executive Officer, Director
- Ryan Daniel Chavez, Chief Financial Officer, General Counsel
- Katharine E. Spink Ph.D., Chief Operating Officer, Executive Vice President
- Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development
- Jane S. Lebkowski Ph.D., Chief Scientific Officer
- Edward D. Wirth III, Chief Medical Officer
- Stephen L. Cartt, Director
- Alfred D. Kingsley, Director
- Aditya P. Mohanty, Director
How do I buy Asterias Biotherapeutics stock?
Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEMKT AST)MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Asterias Biotherapeutics stock can currently be purchased for approximately $2.75.
Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)Earnings History by Quarter for Asterias Biotherapeutics (NYSEMKT AST)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2016||Q316||($0.17)||($0.24)||$1.50 million||$2.10 million||View||N/A|
|8/15/2016||Q216||($0.19)||($0.12)||$1.14 million||$1.53 million||View||Listen|
Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.61 EPS
Next Year EPS Consensus Estimate: $-0.58 EPS
Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Asterias Biotherapeutics (NYSEMKT:AST)Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/9/2017||Edward Wirth||Insider||Sell||3,415||$4.60||$15,709.00|| |
|1/9/2017||Katharine E Spink||COO||Sell||4,781||$4.60||$21,992.60|| |
|10/6/2016||Edward Wirth||Insider||Sell||3,415||$4.12||$14,069.80|| |
|10/6/2016||Katharine E. Spink||COO||Sell||4,781||$4.11||$19,649.91|| |
|9/9/2016||Edward Wirth||Insider||Sell||14,760||$3.52||$51,955.20|| |
|9/9/2016||Katharine E. Spink||COO||Sell||19,336||$3.52||$68,062.72|| |
|6/30/2016||Stephen Lahue Cartt||CEO||Buy||10,000||$2.40||$24,000.00|| |
|6/29/2016||Richard T Lebuhn||Director||Buy||5,000||$2.38||$11,900.00|| |
|6/10/2016||Stephen Lahue Cartt||CEO||Buy||50,000||$2.93||$146,500.00|| |
|6/9/2016||Alfred D Kingsley||Director||Buy||4,000||$2.93||$11,720.00|| |
|5/13/2016||Natale S Ricciardi||Director||Buy||14,706||$3.39||$49,853.34|| |
|9/15/2015||Edward Wirth||insider||Sell||2,880||$6.00||$17,280.00|| |
|9/15/2015||Katharine E. Spink||COO||Sell||3,760||$6.00||$22,560.00|| |
|6/25/2015||Andrew Arno||Director||Buy||5,000||$4.32||$21,600.00|| |
|2/9/2015||Pedro Lichtinger||CEO||Buy||128,205||$3.90||$499,999.50|| |
|10/1/2014||Scarsdale Equities Llc||Major Shareholder||Buy||60,000||$5.93||$355,800.00|| |
Headline Trends for Asterias Biotherapeutics (NYSEMKT:AST)
Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
Loading headlines, please wait.
Asterias Biotherapeutics (AST) Chart for Monday, October, 23, 2017